23h
Hosted on MSNThe Creator Of MASH's Hated Spinoff Thinks This One Change Would Have Saved It (And He's Right)AfterMASH is regarded as one of the worst spinoffs ever produced, but its co-creator thinks one big change could have fixed ...
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
8h
Hosted on MSNMash Madness shakes things upMash Madness has long been a competition among downtown Sioux Falls craft breweries to see who could create the best original ...
Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...
Bariatric surgery reduces the progression to decompensated cirrhosis and the risk for major adverse liver outcomes, such as ...
At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...
Area high schoolers had the chance to experience SUNY Canton’s career-focused healthcare majors first-hand during the ...
Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with ...
9d
News Medical on MSNVitamin E significantly improves liver health in MASH patients, new study findsA 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results